-100
0
100
200
300
% C
hang
e in
Tum
or V
olum
e
0 9 10
-50
-100
0
100
200
300
% C
hang
e in
Tum
or V
olum
e
20 30 40 50 600
500
1000
1500
Days Post Implant
Mea
n Tu
mor
Vol
ume
(mm
3 )
ControlRMC-4630 20 mg/kg po q2dCobimetinib 2.5 mg/kg po qdCombination
Dosingstart
10 20 300
500
1000
1500
Days Post-implant
Mea
n Tu
mor
Vol
ume
(mm
3 )
Dosingstart
ControlRMC-4630 10 mg/kg po qdAMG 510 10 mg/kg po qdCombination
15 25 35 450
250
500
750
1000
Days Post Implant
Mea
n Tu
mor
Vol
ume
(mm
3 )
Dosingstart
0 20 40 60
0
200
400
600
Days on Study
% C
hang
e in
Tum
or v
olum
e
5 10 15 20 25 30 350
500
1000
1500
2000
Days Post Implant
Mea
n Tu
mor
Vol
ume
(mm
3 )
Dosingstart
✱✱
ControlRMC-4550 20 mg/kg po q2dCobimetinib 2.5 mg/kg po qdCombination
10 15 20 25 30 350
1000
2000
3000
Days Post Implant
Mea
n Tu
mor
Vol
ume
(mm
3 )
Dosingstart
*
SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway
JAM Smith1, M Singh1, RJ Nichols1, ES Koltun2, YC Yang1, , D Wildes1, C Stahlhut1, D Lee3, CJ Schulze1, D Reyes1, A Marquez1, G Lee1, S Li4, C Marcireau5, L Debussche5, MA Goldsmith1, 2, 3, 4, ZP Wang3, AL Gill2, SM Kelsey1, 2, 3, 4
Departments of Biology1, Chemistry2, Non-Clinical Development and Clinical Pharmacology3, and Clinical Development4, Revolution Medicines, Redwood City, California; Sanofi Oncology Research5, Vitry, France
1. RMC-4630 is a Potent, Selective and Orally Bioavailable Allosteric Inhibitor of SHP2
3. Single Agent and Combinatorial Benefits of RMC-4630: EGFRmut NSCLC Xenograft Models
2. Single Agent and Combinatorial Benefits of RMC-4630: KRASG12C NSCLC
4. Single Agent and Combinatorial Benefits of RMC-4630: NF1LOF and KRASAmp Xenograft Models
Conclusions• RMC-4630 is a potent, selective and orally bioavailable SHP2 inhibitor which has
shown preliminary signs of clinical activity in patients with NSCLC harboring KRAS mutations, particularly KRASG12C
• In combination with mutant-selective KRASG12C or EGFR inhibitors RMC-4630 can suppress oncoprotein-mediated signaling and adaptive resistance in preclinical models
• SHP2 inhibition alone, or in combination with targeted inhibition of another pathway node such as MEK, exhibited anti-tumor activity in mouse xenograft models with RAS pathway oncogenic drivers, such as NF1LOF, KRASAmp and KRASG12D or KRASG12V for which there are currently no mutant-selective inhibitors
• Translation of these preclinical findings into clinical benefit could position RMC-4630, an investigational therapeutic agent, as a backbone of targeted therapy combinations for patients bearing cancers with diverse oncogenic mutations in the RAS pathway
SHP2 is a Frontier Target in Oncology• Direct targeting of oncogenic mutations in the RAS pathway is a beneficial therapeutic
strategy for patients with cancers with these mutations. Mutant-selective inhibitors offer a wide therapeutic window but are ultimately limited by emergence of drug resistance
• Escape from mutant-selective inhibitors frequently involves activation of wild-type signaling nodes, including hyperactivation of receptor tyrosine kinases (RTKs), that lead to robust re-activation of the RAS pathway
• SHP2 (PTPN11) is a phosphatase that functions as a convergent node downstream of multiple RTKs to regulate RAS activation. We have recently shown that single agent inhibition of SHP2 has anti-tumor activity in tumors harboring KRASG12C both in the clinic and preclinical models1, 2
• In the context of adaptive resistance to mutant-selective inhibitors, SHP2 inhibition has the potential to suppress oncoprotein-mediated signaling and adaptive signaling driving escape from therapy
• For many RAS pathway oncogenic drivers, including KRASG12D and KRASG12V, NF1LOF, KRASAmp or BRAFClass3, mutant-selective inhibitors are not currently available. Here, a combination strategy simultaneously targeting nodes both up- and down-stream of the oncoprotein (“oncoprotein clamping”) can drive tumor growth inhibition
• Here we show that SHP2 inhibitors have the potential to become the backbone of targeted therapy combinations across the spectrum of RAS-dependent tumors
• We have also shown that SHP2 inhibition, alone or in combination, can promote anti-tumor immunity in preclinical models via effects on the innate and adaptive immune systems4, 5. These effects may influence the overall profile of a SHP2 inhibitor
Therapeutic Combinations for RAS Driven Tumors: Mutant-selective and RAS Pathway Node Inhibitors
5. Combination Benefit for SHP2 and MEK Inhibition in Other KRAS-Mutant Xenograft Models
References1. Nichols et al., Nat Cell Biol. 2018 20(9):1064-10732. Ou et al. AACR-IASCLC 20203. Clinical Trials.Gov: NCT036349824. Quintana et al., 2020 Cancer Research 10.1158/0008-54725. Shifrin et al., 2020 AACR A7744 P28376. Planchard et al., Annals Oncology 26: 2073–2078, 2015
Acknowledgements:Jingjing Jiang for expert input into design and execution of in vivo pharmacology modelsCRO support: WuXi AppTec (Suzhou, China); Champions Oncology (Maryland, USA); Charles River Laboratories/OncotestGmbh (Freiburg, Germany); Genendesign (Shanghai, China); Xentech (Evry, France); TD2 (Arizona, USA)
Best Change in Tumor Burden from Baseline NSCLC with any KRAS Mutation for RMC-4630 Monotherapy2, 3
Disease Control Rate: NSCLC KRASmut 12/18 (67%) NSCLC KRASG12C 6/8 (75%)
Data presented for efficacy evaluable population (N = 18) defined as patients with baseline and at least one post-baseline scan or who died or had clinical progression prior to first post-baseline scan.Four patients are not represented in this figure: 2 patients had clinical progression prior to first scan, 1 patient did not have measurements for one of the target lesions but progressed due to new lesion, and 1 patient had missing tumor measurements in the database at the time of data extract.• Confirmed PR # Unconfirmed PR
✘ ✘
Each animal represented as separate barN = number of regressions >10% at end of study; 10 mice/group
Clinical Preclinical NCI-H358 KRASG12C NSCLC Xenograft
• All treatments were well-tolerated
RMC-4630 (PO) PK/PD in vivo
RMC-4630 anti-tumor activity in vivoNCI-H358 KRASG12C NSCLC xenograft
NCI-H358 KRASG12C NSCLC xenograftCompound RMC-4630 RMC-45501
Tool Compound
SHP2 biochemical potency (IC50, nM) 1.29 1.52
RAS pathway suppression (pERK IC50, nM)NCI-H358 KRASG12C 20 28
Anti-proliferative activity (3D CTG IC50, nM)NCI-H358 KRASG12C
NCI-H1975 EGFRL858R/T790M3225
4363
Selectivity- Phosphatase panel- Kinase panel
> 3,000> 3,000
> 3,000> 3,000
SHP2 inhibitors - in vitro profile
KRASG12V Pancreatic
KRASG12V NSCLCNCI-H441
Capan-2
KRASG12D Pancreatic
KP-4 HPAC
LUN #150, NSCLC
CO-04-0004, CRC
STO#332 WT KRASAmp (copy number = 4)
105
KRASAmpNF1LOF
CompoundParental
EGFRL858R/T790M
(IC50, nM)Transfected
EGFRL858R/T790M/C797S (IC50, nM)
RMC-4630 265 218 to 557
Osimertinib 8 30 to 2616
EGFRL858R/T790M/C797S in vitro
EGFRL858R/T790/METAmp NSCLC PDX6
Osimertinib-Sensitive Osimertinib-ResistantNCI-H1975 EGFRL858R/T790M NSCLC CDX
Anti-proliferative activity (2D CTG) in parental NCI-H1975 or cells transfected with human EGFRL858R/T790M/C797S under six different promotersN= 12-15 mice/group
One-way Anova: * p< 0.05; *** p < 0.0001
N = 3 mice/group; graphs show tumor volume data for individual mice, expressed as % of initial tumor volume at time of study start.
N = 12 mice/group; graphs in B show tumor volume data for individual animals shown in A, expressed as % change in tumor volume from time of study start
A
B
Each animal represented as separate barN = number of regressions >10% at end of study; 10 mice/group
Ordinary one-way ANOVA, * p< 0.01, ** p< 0.05, ***p<0.001
LUN #352
• All treatments were well-tolerated
• All treatments were well-tolerated
0 10 20 300
200
400
600
800
Days on Study
Mea
n Tu
mor
Vol
ume
(mm
3 ) ControlRMC-4630 10 mg/kg po qdCobimetinib 2.5 mg/kg po qdCombination
• PDX models of tumors bearing NF1 mutations predicted to result in loss of function (LOF): deletions, insertions, premature stops, truncations
• Tumor growth inhibition in 62% of NF1LOF PDX models (n=55)• Tumor regressions in 25% (23/93) of responders (93/166 mice)
N= 10 mice/group40 80 120 160
0
500
1000
1500
2000
2500
Days Post Implant
Mea
n Tu
mor
Vol
ume
(mm
3 )
ControlOsimertinib 5 mg/kg po qdRMC-4630 30 mg/kg po qdCombination
Initial tumor volume256 mm3
Dosing stopped
40 80 120 160
0
400
800
Days Post Implant
-100
% C
hang
e in
Tum
or V
olum
e
Dosingstopped
Osimertinib 5 mg/kg po qd
40 80 120 160
0
400
800
-100
% C
hang
e in
Tum
or V
olum
e
Days Post-implant
RMC-4630 30 QD + Osimertinib 5 QD
Dosingstopped
40 80
0
100
Days Post Implant
-100
-50
40 80
0
100
-50
-100
Days Post-implant
% C
hang
e in
Tum
or V
olum
e Osimertinib
Combination
1 2 4 8 10 16 241
10
100
1000
10000
0
20
40
60
80
100
Time post-dose (hours)
Unbo
und
Plas
ma
Conc
n(n
M)
% Inhibition pErk/tErkRelative to Control
10 mg/kg30 mg/kg
-9 -8 -7 -6 -50
25
50
75
100
Log Molar [RMC-4630]plasma, unbound
% In
hibi
tion
of p
ERK/
tERK
rela
tive
to c
ontro
l
EC50 = 27 nM
Time post dose2h8h
16h24h
Time post second dose (bid)2h8h
0 10 20 30-100
0
100
200
300
Days on Study
% C
hang
e in
Tum
or V
olum
e
ControlRMC-4630 30 mg/kg po qd
Dose/ schedule
www.revolutionmedicines.com
A5307P1943
0 10 20 300
500
1000
1500
2000
2500
Days on Study
Mea
n Tu
mor
Vol
ume
(mm
3 )
*
***
*#
*** ***
***
*
***0 5 10 15 20 25 30
0
400
800
1200
1600
Days Post Implant
Mea
n Tu
mor
Vol
ume
(mm
3 ) ControlRMC-4630 10 mg/kg po qdRMC-4630 30 mg/kg po qd
Dosingstart
***
*
0
5 10 15 20 250
1000
2000
3000
Days Post Implant
Mea
n Tu
mor
Vol
ume
(mm
3 )
ControlOsimertinib 25 mg/kg po 5d on/2d offRMC-4630 30 mg/kg po qd
Recommended
